Urology department: impact of COVID-19 on prostate cancer diagnosis, treatment and support

Thomas Harding made this Freedom of Information request to Greater Glasgow NHS Board as part of a batch sent to 8 authorities

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was successful.

Dear Greater Glasgow NHS Board,

Prostate Cancer UK are undertaking a Freedom of Information Act (FOI) request of all Trusts, Health Boards and Health and Social Care Trusts, with the aim of assessing the impact of COVID-19 on prostate cancer diagnosis, treatment and support pathways.

Data will be used to identify how we can target future resources to ensure that all patients with suspected prostate cancer have access to pre-biopsy MRI and biopsy, treatment within a safe time period and support, with minimal risk of contracting COVID-19.

We really appreciate your help with this, especially as we understand that there are currently potential limitations on resources. Please pass the below on to your urology department for them to complete. If this is not possible, we would really appreciate your help to provide as much information as you can.

We ask that you please indicate your answer by marking with an “X” next to any answers that apply or by deleting all answers that do not apply. Please avoid answering by italics, underlining or bold, as these do not show up when we process your response.

Yours faithfully,

Thomas Harding (Knowledge Officer, Prostate Cancer UK)

1. Did you suspend your MRI before biopsy service for patients with suspected prostate cancer as a result of the COVID-19 pandemic?
a. Yes
b. No
c. We did not offer MRI before biopsy before the pandemic

2. If yes, have you now resumed MRI before biopsy for patients with suspected prostate cancer?
a. Yes
b. No
c. No, but we refer patients elsewhere (Please state the referral area:)
d. N /A

3. Do you currently use a pre-MRI clinical triage for patients with suspected prostate cancer? By pre-MRI clinical triage, we mean a process, often Clinical Nurse Specialist led, that determines patient suitability for MRI before biopsy
a. Yes
b. No

4. Has your radiology department introduced any new MRI exclusion criteria for patients with suspected prostate cancer as a result of COVID-19?
a. Yes (please specify:)
b. No
c. N/A

5. If yes, do you plan to maintain any of these exclusion criteria once restrictions to limit patients’ COVID-19 risk are lifted?
a. Yes (please specify:)
b. No
c. N/A

6. Did you stop conducting biopsies for patients with suspected prostate cancer as a result of COVID-19 infection risks?
a. Yes
b. No

7. If yes, have you resumed biopsy services for patients with suspected prostate cancer?
a. Yes
b. Yes, but only for a subset of patients (please specify:)
c. No
d. No, but we refer patients elsewhere for prostate biopsy (Please state the referral area:)

8. Do you offer transperineal biopsy under local anaesthetic?
a. Yes
b. No
c. No, but we plan to in future (please specify when if possible:)

9. Following an MRI scan for suspected prostate cancer, what criteria do you use to select patients for biopsy? Please include all that apply:
a. Patients with a PI-RADSs or Likert score of 1 or greater
b. Patients with a PI-RADS or Likert score of 2 or greater
c. Patients with a PI-RADS or Likert score of 3 or greater
d. Patients with a PI-RADS or Likert score of 3 or greater, but only if PI-RADS or Likert score 3 patients have other clinical indications (such as age, ethnicity, PSA density) that make them higher risk
e. Patients with a PI-RADS or Likert score of 4 or greater
f. We do not offer MRI before biopsy
g. We do not currently biopsy patients

10. Did you delay radiotherapy treatment for prostate cancer patients as a result of COVID-19?
a. Yes
b. No
c. Partially (please specify:)
d. N/A (please specify:)

11. If yes, have you cleared your backlog for prostate cancer radiotherapy treatment?
a. Yes
b. No
c. N/A – We did not delay prostate cancer radiotherapy treatment

12. Did you delay radical prostatectomy for prostate cancer patients as a result of COVID-19?
a. Yes
b. No
c. Partially (please specify:)
d. N/A (please specify:)

13. If yes, have you cleared your radical prostatectomy backlog?
a. Yes
b. No
c. N/A – We did not delay radical prostatectomy for prostate cancer patients

14. To address your backlog did or are you using a protocol to risk stratify patients and prioritise patients with high-risk and locally advanced prostate cancer for treatment within 3 months?
a. Yes
b. No
c. No, we did not have a sufficient backlog to require patient prioritisation

15. Does your protocol apply to new patients with high-risk and locally advanced prostate cancer with the intention to radically treat them within 3 months of diagnosis?
a. Yes
b. No
c. N/A - We do not have a protocol for patient prioritisation

16. Do you have prostate cancer Personalised Stratified Follow Up (PSFU) protocols in place?
a. Yes
b. No
c. We are in the process of developing PSFU protocols

17. If Yes, do you have a digital remote monitoring system in place for follow up?
a. Yes (Please specify the name of the system used: e.g My Medical Record, Patient Knows Best)
b. No

18. If no, do you plan to implement a digital remote monitoring system for follow up?
a. Yes - (Please specify the name of the system you plan to implement: e.g My Medical Record, Patient Knows Best)
b. No

19. Which of the following criteria are part of your follow up protocols? (please mark all that apply:)
a. Patients have access to a Support Worker who acts as their key worker for the duration of their follow up care.
b. Patients have access to an online patient service that allows them to check test results, complete assessments, view patient information and message their clinical team.
c. Patients attend a 4-hour supported self-management workshop with a group of 8 to 10 men to develop knowledge, skills and confidence to self-manage their condition
d. Patients do not need to attend routine appointments unless an issue arises.

FOI BOARD HQ, Greater Glasgow NHS Board

Dear Mr Harding

Freedom of Information (Scotland) Act 2002
Environmental Information (Scotland) Regulations 2004
FOI Request 16298: Impact of Covid-19 on prostate cancer treatment

Thank you for your request for information received on 24 September 2020, for information on the impact of Covid-19 on prostate cancer diagnosis, treatment and support, as described in your email below.

We are dealing with this under our procedures for requests made under the Freedom of Information (Scotland) Act 2002, and a response will be issued as soon as possible or within 20 working days as set out in the Act.

If you have any queries about the progress of your request, please contact me at the details below quoting our reference number 16298.

Yours sincerely

Alison Flynn | Freedom of Information Manager | NHS Greater Glasgow & Clyde
Board HQ | J B Russell House | Gartnavel Royal Hospital
1055 Great Western Road | Glasgow | G12 0XH
e:  [NHS Greater Glasgow and Clyde request email]          w:  www.nhsggc.org.uk

When replying please use    [NHS Greater Glasgow and Clyde request email]

**CURRENTLY WORKING REMOTELY**

show quoted sections

FOI BOARD HQ, Greater Glasgow NHS Board

4 Attachments

Dear Mr Harding

 

Freedom of Information (Scotland) Act 2002

FOI Request: Ref 16298 : Impact of COVID-19 on prostate cancer diagnosis,
treatment and support : Response

 

Further to your request for information received on 24 September 2020, I
am now able to provide a response on behalf of NHS Greater Glasgow and
Clyde (NHSGGC).

 

This is attached together with information that describes your right to
request a review and subsequently to appeal to the Scottish Information
Commissioner, if you are dissatisfied with our response or our handling of
your request.

 

I hope this is helpful but if you require further advice and assistance
under the Act, please contact me at the details below.

 

Yours sincerely

Kay Dougans

 

Freedom of Information Officer

NHS Greater Glasgow and Clyde

Corporate HQ

J B Russell House

Gartnavel Royal Hospital Campus

1055 Great Western Road

Glasgow G12 0XH

 

[1][NHS Greater Glasgow and Clyde request email]

 

[2][email address]

 

***WORKING REMOTELY***

 

 

show quoted sections